The Medical Advisor

Weight-loss medications such as Ozempic, Wegovy, Mounjaro, and Zepbound have reshaped obesity treatment. By 2026, millions of people are using GLP-1 receptor agonists or dual GLP-1/GIP drugs to lose weight, improve metabolic health, and reduce cardiometabolic risk. But there’s a hidden issue clinicians are increasingly discussing: Up to 30–40% of the weight lost on GLP-1 therapy can come from lean muscle mass. If that muscle loss isn’t addressed, patients may reach their goal weight but end up with slower metabolism, reduced strength, and higher long-term weight regain risk. This is sometimes called “GLP-1 muscle drain.” The solution isn’t stopping the medication. Instead, experts are increasingly recommending a Protein-Sparing Protocol —a structured approach designed to preserve muscle while maximizing fat loss. Below is the practical, evidence-informed roadmap. 1. The Problem: The “Muscle Drain” Phenomenon GLP-1 medications work primarily by: Slowing gastric emptying Increasing satie...

Semaglutide, known by the brand names Ozempic, Wegovy, Rybelsus and others, is the latest weight-loss craze to hit Hollywood and beyond. The prescription drug, which is administered via a weekly injection, is intended to treat Type 2 diabetes, but it’s widely used off-label for weight loss. They all belong to the same medication class — glucagon-like peptide-1 (GLP-1) agonists ( GLP-1 receptor agonists ).  GLP-1 agonists work by triggering insulin release, blocking sugar production in your liver, and making you feel full. But with all of these brands out there, how do you decide which is right for you? Let’s get to know some of the differences between these major GLP-1 agonist drugs. A 2021 study funded by Novo Nordisk, the drug’s maker, found using semaglutide once a week led to a 14.9% reduction in body weight among adults with obesity. 1  There’s been such a rush on the drugs that the U.S. Food and Drug Administratio...

In the relentless battle against gastrointestinal cancers, esophageal and gastric tumors stand as formidable adversaries, often diagnosed at advanced stages with grim prognoses that leave patients facing palliative care rather than cures. Conventional therapies—chemotherapy, immunotherapy, and radiation—can extend life but frequently exact a heavy toll, prompting many to seek alternatives beyond the standard arsenal. Amid this landscape of desperation and innovation emerges a surprising duo: fenbendazole and ivermectin, antiparasitic agents repurposed from veterinary use that have shown intriguing anticancer properties in preclinical studies and, now, in human anecdotes.  This compilation unveils 20 extraordinary case reports, spanning from hospice-bound elders to vigorous mid-lifers, where these drugs, often combined with minimal supplements or alongside traditional treatments, yielded remissions, tumor shrinkage, and restored quality of life—challenging the boundaries of what's p...